Akums Drugs & Pharmaceuticals Ltd Stock Price Today (NSE: AKUMS)
Fundamental Score
Akums Drugs & Pharmaceuticals Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Akums Drugs & Pharmaceuticals Ltd share price today is ₹466.10, down 3.81% on NSE/BSE as of 30 March 2026. Akums Drugs & Pharmaceuticals Ltd (AKUMS) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹6.70K (Cr). The 52-week high for AKUMS share price is ₹622.95 and the 52-week low is ₹405.00. At a P/E ratio of 21.76x, AKUMS is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 17.19% and a debt-to-equity ratio of 0.03.
Akums Drugs & Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Akums Drugs & Pharmaceuticals Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Akums Drugs & Pharmaceuticals Share Price: A ROCE-Driven Analysis
The pharmaceutical industry is experiencing a dynamic shift, with increasing pressure on companies to demonstrate efficient capital allocation alongside innovative drug development. Today's analysis examines the Akums Drugs & Pharmaceuticals share price, currently at ₹447.75, through the lens of Return on Capital Employed (ROCE). This analysis is part of a comprehensive 80-parameter fundamental audit, verified by Sweta Mishra, focusing on key financial metrics to assess the company's operational efficiency and competitive positioning.
Akums Drugs & Pharmaceuticals Ltd exhibits a Price-to-Earnings (PE) ratio of 21.76, which needs to be considered in light of its profitability. Crucially, the company boasts a ROCE of 16.2%. ROCE, a key indicator of how effectively a company generates profits from its capital, suggests a reasonable level of operational efficiency. This implies that for every ₹100 invested in the business, Akums generates ₹16.2 in earnings before interest and taxes. A higher ROCE generally indicates better profitability and capital management.
One crucial aspect to consider is how this 16.2% ROCE contributes to the company’s moat, or its sustainable competitive advantage. A consistently high ROCE, exceeding the cost of capital, can create a protective barrier against competitors. This allows Akums to reinvest profits at attractive rates, further strengthening its market position and potentially leading to higher valuations over time. However, sustaining this ROCE is key, as new entrants or changing market dynamics could erode this advantage. Comparing Akums' ROCE to its sector peers is essential to benchmark its performance. We can compare this to peers like Mankind Pharma Ltd, Smruthi Organics Ltd, and Balaxi Pharmaceuticals Ltd for a comprehensive peer study.
Moreover, while not explicitly measured by ROCE, management quality plays a vital role. Examining the operational effectiveness of
Mankind Pharma Ltd provides further insight. Examining their strategic decision-making, supply chain management, and cost control measures can offer valuable insights into how Akums Drugs & Pharmaceuticals Ltd fares in terms of management quality relative to its competitors. While a strong ROCE indicates efficient capital utilization, sustained success requires effective leadership and strategic foresight. It is important to note that this analysis is purely observational and does not constitute financial advice.Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Akums Drugs & Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of AKUMS across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Strong Return on Equity (17.19%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (16.20%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 21.76 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Strong Profit Growth Track Record (48.93% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.03)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (6.61x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹132.48 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Profit Decline Concern (-34.83%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Weak Earnings Growth (-42.93% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Akums Drugs & Pharmaceuticals Ltd Financial Statements
Comprehensive financial data for Akums Drugs & Pharmaceuticals Ltd including income statement, balance sheet and cash flow
About AKUMS (Akums Drugs & Pharmaceuticals Ltd)
Akums Drugs & Pharmaceuticals Ltd. is a powerhouse within the Indian pharmaceutical landscape, standing as a comprehensive contract development and manufacturing organization (CDMO...). They function as a vital hub, orchestrating the production of a vast portfolio of pharmaceutical and healthcare solutions, spanning from essential medications to sophisticated formulations. The company's expertise extends across diverse therapeutic areas, catering to both acute and chronic conditions with unwavering commitment to quality and innovation. With a strong foothold in the domestic market, Akums also strategically projects its reach globally, solidifying its position as a reliable partner for pharmaceutical companies seeking manufacturing excellence. This unwavering dedication has positioned Akums as a significant contributor to the healthcare industry, enabling the provision of affordable and quality healthcare solutions for diverse demographics. Beyond conventional pharmaceuticals, Akums embraces a holistic approach to well-being, demonstrated by its involvement in the production of ayurvedic medicines, herbal remedies, and nutraceuticals. This reflects an awareness of the growing consumer demand for natural and alternative therapies, with production conducted under rigorous regulatory standards and quality controls. The company's comprehensive product range further incorporates toiletries, derma and cosmetic products, and food supplements, showcasing its diversification and commitment to addressing various aspects of health and personal care. Akums is dedicated to continuously refining its processes and technologies, ensuring the delivery of products that align with the evolving needs of the healthcare industry. Akums Drugs & Pharmaceuticals Ltd. operates a network of state-of-the-art manufacturing facilities adhering to stringent international quality standards, including certifications from WHO-GMP and other reputed regulatory bodies. This infrastructural strength enables the company to deliver a wide range of dosage forms, including tablets, capsules, liquids, injectables, and topical preparations. Moreover, the company offers a comprehensive suite of services encompassing formulation development, analytical testing, and stability studies, positioning it as a complete solution provider for pharmaceutical companies. By fostering collaborations and partnerships, Akums aims to drive advancements in healthcare, enabling access to quality and affordable medicines for populations worldwide.
Company Details
Key Leadership
Latest News
AKUMS Share Price: Frequently Asked Questions
What is the current share price of Akums Drugs & Pharmaceuticals Ltd (AKUMS)?
As of 30 Mar 2026, 12:03 pm IST, Akums Drugs & Pharmaceuticals Ltd share price is ₹466.10. The AKUMS stock has a market capitalisation of ₹6.70K (Cr) on NSE/BSE.
Is AKUMS share price Overvalued or Undervalued?
AKUMS share price is currently trading at a P/E ratio of 21.76x, compared to the industry average of 31.77x. Based on this relative valuation, the Akums Drugs & Pharmaceuticals Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of AKUMS share price?
The 52-week high of AKUMS share price is ₹622.95 and the 52-week low is ₹405.00. These values are updated daily from NSE/BSE price data.
What factors affect the Akums Drugs & Pharmaceuticals Ltd share price?
Key factors influencing AKUMS share price include quarterly earnings growth (Sales Growth: -1.51%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Akums Drugs & Pharmaceuticals Ltd a good stock for long-term investment?
Akums Drugs & Pharmaceuticals Ltd shows a 5-year Profit Growth of 48.93% and an ROE of 17.19%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.03 before investing in AKUMS shares.
How does Akums Drugs & Pharmaceuticals Ltd compare with its industry peers?
Akums Drugs & Pharmaceuticals Ltd competes with major peers in the Pharmaceuticals. Investors should compare AKUMS share price P/E of 21.76x and ROE of 17.19% against the industry averages to determine competitive standing.
What is the P/E ratio of AKUMS and what does it mean?
AKUMS share price has a P/E ratio of 21.76x compared to the industry average of 31.77x. Investors pay ₹22 for every ₹1 of annual earnings.
How is AKUMS performing according to Bull Run's analysis?
AKUMS has a Bull Run fundamental score of 46.1/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does AKUMS belong to?
AKUMS operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Akums Drugs & Pharmaceuticals Ltd share price.
What is Return on Equity (ROE) and why is it important for AKUMS?
AKUMS has an ROE of 17.19%, which indicates excellent management efficiency. ROE measures how efficiently Akums Drugs & Pharmaceuticals Ltd generates profits from shareholders capital.
How is AKUMS debt-to-equity ratio and what does it indicate?
AKUMS has a debt-to-equity ratio of 0.03, which indicates conservative financing with low financial risk.
What is AKUMS dividend yield and is it a good dividend stock?
AKUMS offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Akums Drugs & Pharmaceuticals Ltd shares.
How has AKUMS share price grown over the past 5 years?
AKUMS has achieved 5-year growth rates of: Sales Growth 11.27%, Profit Growth 48.93%, and EPS Growth -42.93%.
What is the promoter holding in AKUMS and why does it matter?
Promoters hold 75.26% of AKUMS shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Akums Drugs & Pharmaceuticals Ltd.
What is AKUMS market capitalisation category?
AKUMS has a market capitalisation of ₹6697 crores, placing it in the Mid-cap category.
How volatile is AKUMS stock?
AKUMS has a beta of N/A. A beta > 1 suggests the Akums Drugs & Pharmaceuticals Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is AKUMS operating profit margin trend?
AKUMS has a 5-year average Operating Profit Margin (OPM) of 5.62%, indicating the company's operational efficiency.
How is AKUMS quarterly performance?
Recent quarterly performance shows Akums Drugs & Pharmaceuticals Ltd YoY Sales Growth of -1.51% and YoY Profit Growth of -34.83%.
What is the institutional holding pattern in AKUMS?
AKUMS has FII holding of 2.27% and DII holding of 9.28%. Significant institutional holding often suggests professional confidence in the Akums Drugs & Pharmaceuticals Ltd stock.